Gene Rearrangement Clinical Trials

11 recruitingLast updated: June 18, 2026

There are 11 actively recruiting gene rearrangement clinical trials across 20 countries. Studies span Phase 2, Not Applicable, Phase 1. Top locations include Dallas, Texas, United States, Madrid, Spain, Barcelona, Spain. Updated daily from ClinicalTrials.gov.


Gene Rearrangement Trials at a Glance

11 actively recruiting trials for gene rearrangement are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Dallas, Madrid, and Barcelona. Lead sponsors running gene rearrangement studies include The First Affiliated Hospital of Soochow University, Massive Bio, Inc., and Groupe Francais De Pneumo-Cancerologie.

Browse gene rearrangement trials by phase

Treatments under study

About Gene Rearrangement Clinical Trials

Looking for clinical trials for Gene Rearrangement? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gene Rearrangement trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gene Rearrangement clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement
Taiho Oncology, Inc.120 enrolled65 locationsNCT05727176
Recruiting
Phase 2

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce38 enrolled2 locationsNCT06728410
Recruiting

A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT

Acute LeukemiaMenin InhibitorsPost Hematopoietic Stem Cell Transplantation+4 more
The First Affiliated Hospital of Soochow University20 enrolled1 locationNCT07559695
Recruiting
Not Applicable

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie100 enrolled46 locationsNCT05122806
Recruiting
Phase 2

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

NSCLCBrain MetastasesROS1 Gene Rearrangement
MedSIR20 enrolled16 locationsNCT06315010
Recruiting
Phase 1

Study of SGR-1505 in Mature B-Cell Neoplasms

High-grade B-cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+23 more
Schrödinger, Inc.98 enrolled36 locationsNCT05544019
Recruiting

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Breast CancerOvarian CancerEndometrial Cancer+40 more
Massive Bio, Inc.50,000 enrolled68 locationsNCT03452774
Recruiting
Phase 2

Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia

Acute LeukemiaMenin InhibitorsPost Hematopoietic Stem Cell Transplantation+4 more
The First Affiliated Hospital of Soochow University60 enrolled1 locationNCT07101497
Recruiting
Phase 2

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Stage IV Non-Small Cell Lung CancerMET AmplificationNon-squamous Non-small Cell Lung Cancer+2 more
University Health Network, Toronto50 enrolled1 locationNCT04084717
Recruiting
Not Applicable

Mutational Oncology in Clinical Practice

Genetic Predisposition to DiseaseGene RearrangementGenome Instability
Fondazione Policlinico Universitario Agostino Gemelli IRCCS20,000 enrolled1 locationNCT06020625
Recruiting
Phase 1Phase 2

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

DLBCLUntreatedMYC Gene Rearrangement
The First Affiliated Hospital with Nanjing Medical University81 enrolled1 locationNCT04432714